NCT00149292View on ClinicalTrials.gov

Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

August 23, 2005

Primary Completion Date

July 17, 2006

Study Completion Date

July 17, 2006

Conditions
Schizophrenia
Interventions
DRUG

LY2140023

DRUG

olanzapine

DRUG

placebo

Trial Locations (2)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Moscow

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Village Nikolskoe

Sponsors
All Listed Sponsors
lead

Denovo Biopharma LLC

INDUSTRY

NCT00149292 - Study of LY2140023 in Schizophrenia Comparing LY2140023, Olanzapine, and Placebo | Biotech Hunter | Biotech Hunter